Menu
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Fribourg, Switzerland.
rue Louis-d'Affry 6
http://www.alcon.com
Alcon, the global leader in eye care dedicated to helping people see brilliantly, will present a robust lineup of scientific
LONDON and RALEIGH, N.C., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ: VRNA ) ("Verona Pharma"), announces effective September 1, 2023, Ms. Christina Ackermann will join the board as a Non-Executive Director. Ms. Ackermann brings over 25 years of legal and management experience across the pharmaceutical, device and consumer products industries. Most recently, she served as Executive Vice President, General Counsel and Global President Ophthalmic Pharmaceuticals at Bausch + Lomb Corporation where she was responsible for strategic planning and worldwide commercialization of pharmaceutical prescription assets across the portfolio as well as global legal affairs. Previously, Ms. Ackermann was part of the Novartis group of companies for 14 years where she served in multiple leadership roles of increasing responsibility including Global Head, Legal and General Counsel of Alcon and Sandoz. Earlier in her career, Ms. Ackermann held Associate General Counsel roles at both Bristol-Myers Squibb and DuPont Pharmaceuticals. "We are pleased to welcome Christina to the Board," said Dr.
JP Morgan’s European desk has upgraded Alcon (ALC) to overweight, commenting that concerns about growth in the implantables market is likely to be “short-lived.” Read more here.
David Endicott, CEO of Alcon, discusses its second-quarter earnings.
https://www.investing.com/news/pro/alcon-n-receives-investment-bank-analyst-rating-update-3156020
https://www.investing.com/news/pro/alcon-ag-receives-investment-bank-analyst-rating-update-3156019
Alcon Inc. (NYSE:NYSE:ALC) Q2 2023 Earnings Conference Call August 16, 2023 8:00 AM ETCompany ParticipantsDaniel Cravens - Vice President, Investor RelationsDavid Endicott - Chief Executive…
Alcon (ALC) is scheduled to announce Q2 earnings results on Wednesday, August 16th, after market close.The consensus EPS Estimate is $0.65 (+3.2% Y/Y) and the consensus Revenue Estimate…
Alcon press release (ALC): Q2 Non-GAAP EPS of $0.69 beats by $0.04.Revenue of $2.4B (+9.1% Y/Y) beats by $20M.2023 Outlook: Net sales $9.3 to $9.5 billion; Change vs
Second quarter 2023 sales of $2.4 billion, up 9%, or 12% constant currency(1) (cc) Second quarter 2023 diluted EPS of $0.34, up 13%, or up 34% cc; core diluted EPS(2) of $0.69 up 10%, or 19% cc Ba…